1. Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult-to-Treat HCV Patients
- Author
-
Régine Truchi, Denis Ouzan, Magdalena Meszaros, Marc Bourlière, Georges Philippe Pageaux, Albert Tran, Département d'Hépato-Gastroentérologie et de Transplantation Hépatique [CHU Saint-Eloi], Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université de Montpellier (UM), Université Côte d'Azur (UCA), Hôpital Archet 2 [Nice] (CHU), Institut Arnault Tzanck, Service d'hépatologie et de gastroentérologie [Hôpital Saint-Joseph - Marseille], and Aix Marseille Université (AMU)-Hôpital Saint-Joseph [Marseille]
- Subjects
0301 basic medicine ,Cyclopropanes ,Liver Cirrhosis ,Male ,Aminoisobutyric Acids ,Pyrrolidines ,Sofosbuvir ,Sustained Virologic Response ,MESH: Sustained Virologic Response ,MESH: Sulfonamides ,Hepacivirus ,medicine.disease_cause ,Gastroenterology ,chemistry.chemical_compound ,MESH: Cyclopropanes ,0302 clinical medicine ,MESH: Drug Monitoring ,Medicine ,MESH: Hepacivirus ,MESH: Treatment Outcome ,Sulfonamides ,MESH: Middle Aged ,MESH: Drug Resistance, Viral ,virus diseases ,Hepatitis C ,Middle Aged ,MESH: Hepatitis C, Chronic ,MESH: Aminoisobutyric Acids ,Treatment Outcome ,030211 gastroenterology & hepatology ,Female ,MESH: Liver Cirrhosis ,Drug Monitoring ,medicine.drug ,MESH: Antiviral Agents ,medicine.medical_specialty ,Proline ,Medication Therapy Management ,Voxilaprevir ,Hepatitis C virus ,Lactams, Macrocyclic ,Antiviral Agents ,03 medical and health sciences ,MESH: Quinoxalines ,MESH: Ribavirin ,Rescue therapy ,Leucine ,Internal medicine ,Quinoxalines ,Drug Resistance, Viral ,Ribavirin ,Humans ,MESH: Proline ,MESH: Pyrrolidines ,MESH: Humans ,Hepatology ,business.industry ,MESH: Sofosbuvir ,MESH: Lactams, Macrocyclic ,[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology ,Hepatitis C, Chronic ,medicine.disease ,MESH: Male ,MESH: Leucine ,030104 developmental biology ,chemistry ,Benzimidazoles ,Glecaprevir / pibrentasvir ,MESH: Benzimidazoles ,business ,MESH: Medication Therapy Management ,MESH: Female ,Velpatasvir - Abstract
International audience; Pangenotypic direct-acting antiviral (DAA) drugs have an HCV cure rate of >95% in almost all treated patients.(1, 2) When DAA treatment fails, retreatment must be guided by virus resistance profiles, and phase 3 trials have reported sustained virological responses (SVR) of 96%-98% after a 12-week course of sofosbuvir (SOF), velpatasvir (VEL), and voxilaprevir (VOX).(3) However, the management is more uncertain after SOF/VEL/VOX failure, and there is still insufficient evidence to support a particular retreatment. For instance, Dietz et al.(4) reported 77% SVR at 12 weeks (SVR12) in patients with different HCV profiles retreated with glecaprevir (GLE)/pibrentasvir (PIB), SOF, and ribavirin (RBV) for 12-24 weeks after SOF/VEL/VOX failure.
- Published
- 2021
- Full Text
- View/download PDF